Avantor, Inc. (NYSE:AVTR) Shares Sold by Vaughan Nelson Investment Management L.P.

Vaughan Nelson Investment Management L.P. lowered its stake in shares of Avantor, Inc. (NYSE:AVTR) by 5.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,084,416 shares of the company’s stock after selling 59,760 shares during the quarter. Vaughan Nelson Investment Management L.P. owned approximately 0.16% of Avantor worth $22,849,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of the stock. MassMutual Private Wealth & Trust FSB boosted its holdings in shares of Avantor by 99.5% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,253 shares of the company’s stock valued at $26,000 after acquiring an additional 625 shares during the period. UMB Bank n.a. acquired a new stake in Avantor during the 3rd quarter worth $49,000. Nisa Investment Advisors LLC grew its position in Avantor by 69.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company’s stock worth $53,000 after purchasing an additional 835 shares during the last quarter. GAMMA Investing LLC increased its stake in Avantor by 89.9% in the third quarter. GAMMA Investing LLC now owns 2,715 shares of the company’s stock valued at $70,000 after purchasing an additional 1,285 shares during the period. Finally, Livforsakringsbolaget Skandia Omsesidigt raised its holdings in shares of Avantor by 278.0% in the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 5,031 shares of the company’s stock valued at $130,000 after buying an additional 3,700 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Raymond James dropped their price target on Avantor from $29.00 to $26.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 21st. Wells Fargo & Company dropped their target price on Avantor from $30.00 to $28.00 and set an “overweight” rating on the stock in a report on Monday, October 28th. Barclays increased their price target on Avantor from $25.00 to $26.00 and gave the stock an “overweight” rating in a report on Monday, February 3rd. Robert W. Baird dropped their price objective on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a research note on Monday, October 28th. Finally, UBS Group restated a “neutral” rating and issued a $25.00 target price (down previously from $29.00) on shares of Avantor in a research note on Friday, January 17th. Three equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $27.46.

Avantor Stock Performance

NYSE AVTR opened at $19.15 on Monday. The business has a 50 day moving average price of $21.73 and a 200 day moving average price of $23.46. The company has a market capitalization of $13.03 billion, a P/E ratio of 41.63, a PEG ratio of 3.87 and a beta of 1.28. Avantor, Inc. has a 1-year low of $19.08 and a 1-year high of $28.00. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.54 and a quick ratio of 1.06.

Avantor (NYSE:AVTR) last announced its quarterly earnings results on Wednesday, February 12th. The company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.26 by $0.01. Avantor had a return on equity of 12.24% and a net margin of 4.54%. During the same period in the previous year, the company earned $0.22 earnings per share. Sell-side analysts expect that Avantor, Inc. will post 0.98 EPS for the current fiscal year.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.